Neogen Chemicals Q2 FY27 Results (NSE: NEOGEN)
Signal: Growth reaccelerated
The read
The trajectory is shifting from core-business resilience to battery-chemicals scale-up: revenue accelerated to INR 296 crore, up 42% YoY, and Neogen Ionics reached INR 37 crore, but EBITDA margin was only 15.2% because the new platform is absorbing costs before full utilisation; the next inflection depends on electrolyte and salt commissioning and Q4FY27 scale-up.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹296 Cr | +42% | N/A |
| Net profit | ₹8 Cr | +144% | |
| EPS | ₹2.96 | N/A | |
| EBIT margin | 15.2% |
P&L walk
Consolidated revenue increased 42% YoY to INR 296 crore, gross profit rose 36% to INR 133 crore, EBITDA grew 51% to INR 45 crore and PAT increased 144% to INR 8 crore; however, higher interest, depreciation, NIL ramp-up costs and elevated feedstock costs limited profit conversion.
Segments
Neogen Ionics is the clear growth engine, contributing INR 37 crore of Q2 revenue versus INR 5.4 crore a year earlier, although its initial fixed-cost absorption is currently dragging consolidated margin conversion.
Key positives
- Revenue rose 42% YoY to INR 296 crore, with growth supported by sustained core-segment volume expansion despite geopolitical, supply-chain and feedstock-cost pressures.
- Neogen Ionics revenue increased to INR 37 crore from INR 5.4 crore a year earlier, showing early commercial traction in battery chemicals.
- EBITDA grew 51% YoY to INR 45 crore, ahead of 42% revenue growth, despite initial fixed-cost absorption at NIL and ongoing Dahej rebuild costs.
- The INR 600 crore QIP was oversubscribed 6.5x, providing funding for debt reduction and incremental battery-chemicals growth requirements.
- Battery-chemicals execution advanced with 1,000 MTPA commissioned in Q2FY27, commercial supply started with two customers, and provisional approvals secured from five major international customers.
Key concerns
- Gross profit grew 36% YoY to INR 133 crore, below 42% revenue growth, while the filing attributes pressure to elevated feedstock costs and does not disclose the precise gross-margin movement.
- PAT of INR 8 crore remains small relative to INR 45 crore EBITDA because higher interest and depreciation from ongoing capex initiatives are temporarily suppressing earnings conversion.
- Neogen Ionics is generating INR 37 crore of revenue but is still in ramp-up, with initial fixed-cost absorption and capacity utilisation below the level required for full operating contribution.
- Cumulative battery-chemicals CAPEX of INR 1,537 crore has been deployed against a total estimated project cost of INR 1,795 crore, increasing execution and utilisation risk.
Research and educational content only. Not investment advice.